Impel Pharmaceuticals Profit Margin

The latest profit margin for IMPL is -394.73% as of September 2023. That compares with -1313.87% in the prior-year period — up 70.0% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Impel Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMPL's profit margin moved from -1313.87% to -394.73% — a 70.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Impel Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, IMPL currently prints -394.73% for profit margin, while the sector average sits near 14.34%. That is roughly 2851.8% below the sector mean. Large gaps often invite a closer look at Impel Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Impel Pharmaceuticals converts resources into returns. At -394.73%, IMPL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1313.87% in the prior-year period — up 70.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IMPL's profit margin (-394.73%), review year-over-year change from -1313.87%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.